Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Heart Failure, Pulmonary Hypertension

In brief

This study is a multi-center, prospective, randomized, double blind, placebo-controlled clinical trial. Subjects in the study will be adults with New York Heart Association (NYHA) Class II-IV heart failure (HF) due to left ventricular systolic dysfunction (LVSD), left ventricular ejection fraction (LVEF) \<0.40, and secondary pulmonary hypertension (PH). The purpose of the study is to evaluate the safety, effectiveness, and effects of tadalafil compared to placebo on the subjects' functional capacity / quality of life.

Key facts

Study ID

NCT01910389

Run by

Carelon Research

People needed

23

Starts

2013-11-01

Expected to finish

2014-02-01

Last updated by the study team

2015-05-04

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female age 21 years or older.
• NYHA Class II-IV HF with LVSD (most recent LVEF < 0.40).
• At high risk of future clinical instability, indicated by EITHER:
• a hospitalization for the primary reason of decompensated HF within the 12 months prior to screening; OR a plasma B-type Natriuretic Peptide (BNP) level ≥ 300 pg/ml or N-terminal prohormone of brain natriuretic peptide (NT-proBNP) ≥1800pg/ml measured during a period of clinical stability in the 3 months prior to screening.
• Documented secondary PH within the last 6 months
• Medication and device treatment according to current American Heart Association/American College of Cardiology (AHA/ACC) guidelines.
• Stable medical therapy for 30 days prior to randomization
• African-American patients intolerant of or otherwise unable or unwilling to utilize isosorbide dinitrate/hydralazine therapy will be included.
• Willingness to comply with protocol, attend follow-up appointments, complete all study assessments and provide written informed consent.

You may not qualify if…

• Concurrent or anticipated nitrate use for any reason, or nitrate use within the 14 days prior to screening through the day of randomization.
• Known allergy, hypersensitivity (anaphylaxis), or adverse reaction to tadalafil or other Phosphodiesterase Type 5 (PDE5) inhibitor
• Erectile dysfunction treated with a PDE5 inhibitor.
• Severe renal dysfunction defined as an estimated glomerular filtration rate (GFR) < 30 ml/min/1.73 m\^2 or requiring chronic dialysis
• Current use of alpha antagonists (except carvedilol or tamsulosin) or use of cytochrome P450 3A4 inhibitors (ketoconazole, itraconazole, erythromycin, or cimetidine). Patients who have used a protease inhibitor that is a P450 3A4 inhibitor for longer than one week can be enrolled.
• Pulmonary arterial hypertension (World Health Organization (WHO) Group I, III-V) for which PDE5 inhibitor therapy may be indicated
• Severe pulmonary disease requiring home oxygen therapy
• Comorbidities including clinically significant valvular stenosis (aortic valve area < 0.8 cm\^2 or a mitral valve area <1.0 cm\^2), uncontrolled hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg) or hypotension (systolic blood pressure <85 mmHg)
• Chronic intravenous inotrope therapy
• Non-arteritic anterior ischemic optic neuropathy (NAION)
• ST elevation MI (STEMI) within 90 days prior to screening
• Coronary Artery Bypass Grafting (CABG) or mitral valve surgery, initiation of cardiac resynchronization (CRT) or initiation of β-blocker therapy within the 6 months prior to screening
• Infiltrative or inflammatory myocardial disease (e.g. amyloid, sarcoid)
• Heart transplant recipient
• United Network Organ Sharing (UNOS) status 1A or 1B
• Mechanical circulatory support (MCS) use or planned MCS use at time of consent
• Active malignancy (except non-melanoma skin cancer) requiring therapy other than observation.
• Severe non-cardiac illness resulting in life expectancy judged less than three years
• Known chronic hepatic disease defined as aspartate aminotransferase (AST) and alanine transaminase (ALT) levels > 3.0 times the upper limit of normal
• Inability to walk even a few steps due to non-cardiac (e.g. orthopedic) reasons
• Participation in any clinical trial within the last 30 days (with exception of observational study)
• Previous randomization in PITCH-HF

Where it is running

• Baptist Health Transplant Institute — Little Rock, Arkansas, United States
• Allianz Medical and Research Center — Fountain Valley, California, United States
• Christiana Care Health System — Newark, Delaware, United States
• Broward Health — Fort Lauderdale, Florida, United States
• Miller School of Medicine University of Miami — Miami, Florida, United States
• Orlando Health — Orlando, Florida, United States
• Charlotte Heart Group Research Center — Port Charlotte, Florida, United States
• Brevard Cardiovascular Research Associates — Rockledge, Florida, United States
• University Cardiology Associates LLC — Augusta, Georgia, United States
• Eisenhower Army Medical Center — Fort Gordon, Georgia, United States
• Northwestern University — Chicago, Illinois, United States
• University of Illinois Hospital — Chicago, Illinois, United States
• Methodist Medical Group Cardiology — Peoria, Illinois, United States
• Baptist Hospital East — Louisville, Kentucky, United States
• Research Integrity LLC — Owensboro, Kentucky, United States
• LSU Health Sciences Center — New Orleans, Louisiana, United States
• Maine Research Associates — Auburn, Maine, United States
• Johns Hopkins Hospital — Baltimore, Maryland, United States
• Primary Care Cardiology Research, Inc. — Ayer, Massachusetts, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• MGH West — Waltham, Massachusetts, United States
• University of Michigan Health System — Ann Arbor, Michigan, United States
• Oakwood Hospital and Medical Center — Dearborn, Michigan, United States
• Heart Center Inc - Research — Huntsville, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.